Deakin University
Browse

File(s) under permanent embargo

Advances in the treatment of malignant gliomas

journal contribution
posted on 2010-01-01, 00:00 authored by Mustafa Khasraw, A Lassman
Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval by the US Food and Drug Administration as a single agent for recurrent glioblastoma. Recent trial results are generating important clinical questions regarding which patients to treat and when, and how best to monitor response. Encouraging results of recent studies are driving willingness to undertake aggressive treatment and to improve outcomes in this population. In this era, better understanding of biology, molecular aspects of cancer, and clinical trial methodology are crucial for clinicians. This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy.

History

Journal

Current oncology reports

Volume

12

Issue

1

Pagination

26 - 33

Publisher

Springer Healthcare

Location

Philadelphia, Pa.

ISSN

1523-3790

eISSN

1534-6269

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

2010, Springer Science+Business Media, LLC